Your session is about to expire
← Back to Search
177Lu-DOTA-EB-TATE for Neuroendocrine Cancer
Study Summary
This trial is to test a new treatment for a rare cancer. It will study how well the treatment works and what side effects it may have.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't used somatostatin or its analogues in the last 4 months.I had local therapy over 4 weeks ago.I have tumors that cannot be treated with local therapies before starting the treatment.I have no other cancers except for possibly non-melanoma skin cancer or treated cervical carcinoma in situ.My bone marrow is not working well.My brain metastases have been treated and are now stable.I cannot stop my octreotide treatment for 24 hours before and after receiving 177Lu-DOTA-EB-TATE.My last surgery was more than 6 weeks ago.I have had more than 4 treatments with 177Lu-DOTA-TATE.I am not pregnant or breastfeeding.I am 18 years old or older.I have severe urinary incontinence making certain cancer treatments unsafe for me.I haven't had cancer treatment or experimental drugs in the last 4 weeks or longer.I am still recovering from a major surgery or injury, or expect to have major surgery soon.My liver is not working well.My kidney function is reduced with a creatinine level over 1.7 mg/dL.I do not have any serious infections like HBV, HCV, HIV, or AIDS.I am able to care for myself but may not be able to do active work.I have not been treated with 177Lu-DOTA-TATE or had no cancer growth for 12 months after treatment.My kidneys are functioning well.My scan shows high levels of certain receptors in at least one cancer lesion.I've had radiation therapy that affected more than a quarter of my bone marrow.Over 80% of my liver is affected by cancer.My tumor is a confirmed, inoperable neuroendocrine tumor of the GI or pancreas.My cancer has spread to over 25% of my bone marrow.My cancer is a type of aggressive neuroendocrine tumor.My side effects from previous treatments have mostly gone away.My neuroendocrine tumor is classified as grade 1, 2, or 3.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.
- Group 1: Peptide Receptor Radionucleotide Therapy (PRRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree is 177Lu-DOTA-EB-TATE hazardous to human health?
"Owing to the data collected during Phase 1, our team at Power has assigned a score of 1 for 177Lu-DOTA-EB-TATE's safety rating. This indicates that there is limited evidence attesting to its efficacy and security."
How many participants are enrolled in this experimental research?
"Affirmative. According to the information available on clinicaltrials.gov, this medical investigation is actively recruiting patients and has been since its initial posting date of June 18th 2022. 9 applicants are required from 1 location for the successful completion of this trial."
Are enrollees still being accepted into this research trial?
"Affirmative. According to the information published on clinicaltrials.gov, this trial initially posted on June 18th 2022 is currently recruiting participants. A total of 9 participants need to be enrolled from 1 medical site."
Share this study with friends
Copy Link
Messenger